Cadence Pharmaceuticals Prices IPO

San Diego-based Cadence Pharmaceuticals has priced the firm's IPO, saying that it will offer 6,00,000 shares of common stock at $9 per share. Cadence develops pharmaceuticals for hospitals, including candidates for the treatment of acute pain and catheter-related infections. The firm will list on the NASDAQ under the symbol CADX. The IPO is being underwritten by Merrill Lynch & Co., Deutsche Bank Securities, Pacific Growth Equities, and JMP Securities. The firm is backed by BB Biotech Ventures, CDIB Ventures, Domain Associates, Frazier Healthcare Ventures, Proquest Investments, Technology Partners, Versant Ventures, Windamere Venture Partners and others.